SUPPLY AND FULFILMENTThis is the page where businesses in this category died in 2025, and the page where the next round of deaths is already scheduled on a public docket.

Educational overview · Approx. 4 min read · illustrative, not advice

This is the page where businesses in this category died in 2025, and the page where the next round of deaths is already scheduled on a public docket.

What happened in 2025

FDA removed tirzepatide from the shortage list in December 2024, with compounders expected to cease by March 2025. FDA declared the injectable semaglutide shortage resolved on February 21, 2025; enforcement discretion for 503A compounding pharmacies ended April 22, 2025 and for 503B outsourcing facilities on May 22, 2025.

A large number of businesses in this category had built their entire supply position, and therefore their entire price position, on shortage-era compounding. When the shortage ended, so did the legal basis for the supply. That is not a market shock. It was a foreseeable end date on a temporary permission, and it was foreseeable from the day the permission was granted.

The lesson generalises past GLP-1s: a supply position that exists because of a temporary regulatory condition is a countdown, not a moat.

What FDA says about compounded product

FDA states that a compounded product may contain the same active ingredient but is not the drug FDA reviewed and approved, and that FDA does not evaluate specific compounded products for safety, effectiveness, manufacturing quality or consistency.

FDA has received hundreds of adverse event reports associated with compounded semaglutide and tirzepatide, including reports linked to dosing errors, and has warned about fraudulently labelled product naming pharmacies that do not exist. In September 2025 FDA issued more than 50 warning letters to companies compounding or manufacturing semaglutide and tirzepatide over statements it deemed false or misleading.

That last item is a marketing enforcement fact as much as a supply fact. Read page ten with it in mind.

The live risk, with its dates

On April 30, 2026 FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulk drug substances list, finding no clinical need for outsourcing facilities to compound them from bulk substance and expressly rejecting affordability and insurance access as constituting clinical need. The comment period was extended, with comments due July 30, 2026.

Note the reasoning, not just the outcome. FDA specifically declined to treat cost and coverage as a clinical justification. Any business model whose supply argument is that compounded product is cheaper for people who cannot afford branded product has been addressed directly by the regulator and told that argument does not count.

This is the single most consequential open item in the category as of this writing, and any seller of a build who cannot discuss it by name and date is not current.

What the market did anyway

IQVIA reported in October 2025 that compounded GLP-1 prescribing did not abate after delisting. More than 80% of compounded prescriptions include supplemental ingredients such as B vitamins or levocarnitine. Anti-obesity patients were approximately 83% of the compounded GLP-1 market during the shortage period, and roughly 2% of compounded patients switched to branded products monthly.

The supplemental-ingredient figure is the tell. Adding an ingredient is a common route to arguing a compounded product is not essentially a copy of an approved drug. Whether any specific formulation is permissible is a legal and regulatory question for the compounding entity, the prescriber and their counsel, not a marketing question and not one a build seller should be answering for you.

The 2% monthly switching figure tells you something else: this is a sticky channel, which means a supply disruption inside it does not resolve itself gently.

What a durable supply position looks like

Three properties. First, it does not depend on a temporary regulatory condition. Second, it survives price compression, because manufacturers are now selling direct at falling prices as page four describes, so any margin that exists solely because of a price gap on a molecule is borrowed. Third, it is documented: you can name the entity, see its registrations, and produce provenance for what a member receives.

Supplements and non-prescription components have their own supply chain with its own failure modes, and our library covers how those chains actually work, including who manufactures, who labels and where quality claims come from.

We make no efficacy claims about any medication or supplement in this document, and neither should any material you publish. Ask Atlas to put this in writing: the specific fulfilment relationships included in an Atlas build, named entity by entity, so partners can verify registrations themselves

FREQUENTLY ASKED QUESTIONS.